Login / Signup
Response to a combination of erlotinib and bevacizumab therapy after immune checkpoint inhibitor.
Shinichiro Okauchi
Kunihiko Miyazaki
Hideyasu Yamada
Toshihiro Shiozawa
Published in:
The clinical respiratory journal (2020)
Keyphrases
</>
advanced non small cell lung cancer
epidermal growth factor receptor
metastatic colorectal cancer
mesenchymal stem cells
tyrosine kinase